Evidence map›Paper›PMID 35625992›Full record

ArticleCancers2022

Urine Cell-Free MicroRNAs in Localized Prostate Cancer Patients.

Yoko Koh, Matias A Bustos, Jamie Moon, Rebecca Gross, Romela Irene Ramos, Suyeon Ryu, Jane Choe, Selena Y Lin, Warren M Allen, David L Krasne and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yoko KohDepartment of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA.ORCID 0000-0001-9976-6994
Matias A BustosDepartment of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA.ORCID 0000-0001-9625-1127
Jamie MoonDepartment of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA.
Rebecca GrossDepartment of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA.ORCID 0000-0002-1175-5789
Romela Irene RamosDepartment of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA.
Suyeon RyuGenome Sequencing Center, Saint John's Cancer Institute (SJCI), Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA.
Jane ChoeDepartment of Urology and Urologic Oncology, Saint John's Cancer Institute (SJCI), Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA.
Selena Y LinJBS Science Inc., Doylestown, PA 18902, USA.
Warren M AllenDivision of Surgical Pathology, Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA.
David L KrasneDivision of Surgical Pathology, Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA.
Timothy G WilsonDepartment of Urology and Urologic Oncology, Saint John's Cancer Institute (SJCI), Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA.
Dave S B HoonDepartment of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA.

Funding

Martin and Pauline Collins Family, Ensign foundation NAThe ABCs foundation NA
6 · The paper itself

Abstract

Prostate cancer (PCa) is the most common cancer in men. Prostate-specific antigen screening is recommended for the detection of PCa. However, its specificity is limited. Thus, there is a need to find more reliable biomarkers that allow non-invasive screening for early-stage PCa. This study aims to explore urine microRNAs (miRs) as diagnostic biomarkers for PCa. We assessed cell-free miR (cfmiR) profiles of urine and plasma samples from pre- and post-operative PCa patients (

Indexed as

cell-free microRNAdiagnosismicroRNAplasmaprostate cancerurine

Identifiers

PMID35625992
PMCPMC9139357

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.